Skip to main content
. 2013 Jan 17;14(2):302–310. doi: 10.1021/bm301858a

Figure 8.

Figure 8

Assessment of cytotoxicity of DR5-targeted chitosan/alginate nanoparticles by DR5 silencing and caspase 8 activation toward HCT116. (A) Treatment with comparable ratios of DR5-targeted nanoparticles and free anti-DR5 antibody for 15 h, followed by analysis of caspase 8 activity using caspase Glo 8 substrate (Promega). (B) FACS analysis of DR5 silencing using PE labeled anti-DR5 (clear peak) and IgG isotype control antibodies (filled peak). (C) Incubation of blank DR5-targeted nanoparticles for 16 h with DR5 silenced and control HCT116 cells prior to a further 12 h incubation and assessment of cell viability by MTT assay. ***p < 0.005.